Azitra, Inc. (AZTR) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing genetically engineered microbes and proteins for precision dermatology. The company is in the pre-commercialization phase with no product revenue. This report covers the quarterly period ended September 30, 2024. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $0 | $310,700 | $7,500 | $596,000 |
| Net Loss | $(1,009,491) | $(1,943,289) | $(6,574,359) | $(8,829,996) |
| Operating Expenses | $2,929,207 | $2,304,432 | $8,558,484 | $5,576,069 |
| Cash and Equivalents (End of Period) | $7,260,234 | $4,400,327 | $7,260,234 | $4,400,327 |
| Working Capital | $6,266,863 | $932,384 | $6,266,863 | $932,384 |
| Accumulated Deficit | $(55,172,692) | $(46,144,549) | $(55,172,692) | $(46,144,549) |
Liquidity and Debt: As of September 30, 2024, the company held approximately $7.3 million in cash. Total liabilities were $1.7 million, consisting primarily of operating and financing lease liabilities. There is no long-term debt outstanding; previous convertible notes were converted to equity in 2023.
Material Changes vs. Prior Period
- Revenue Decline: Service revenue from the related party (Bayer) dropped to $0 in Q3 2024 from $310,700 in Q3 2023 due to a decrease in reimbursable development costs.
- Expense Increases: Operating expenses increased 27% quarter-over-quarter. Research and Development (R&D) expenses rose 85% to $1.0 million, driven by clinical trial preparations for ATR-12 and ATR-04. General and Administrative (G&A) expenses increased 9% to $1.9 million, reflecting public company costs and executive compensation.
- Non-Cash Gains/Losses: The net loss was significantly impacted by a $4.0 million gain from the change in fair value of warrants (due to a reset provision) and a $2.1 million loss on the issuance of common stock related to the July 2024 follow-on offering.
- Capital Structure: The company completed a 30-for-1 reverse stock split in July 2024 and a follow-on public offering in July 2024, raising approximately $9.1 million in net proceeds.
Outlook, Risks, and Management Commentary
- Going Concern: Management has identified substantial doubt about the company's ability to continue as a going concern for the next 12 months due to an accumulated deficit of $55.2 million and a lack of commercial revenue. Additional financing is required to fund operations and clinical trials.
- Clinical Pipeline:
- ATR-12: First patient dosed in August 2024 for Netherton syndrome; initial safety results expected Q1 2025.
- ATR-04: Received FDA Fast Track designation in September 2024 for EGFRi-associated rash; Phase 1b trial expected to commence Q4 2024.
- ATR-01: Targeting ichthyosis vulgaris; IND filing targeted for early 2026.
- Internal Controls: The company identified a material weakness in internal controls related to a lack of adequate segregation of accounting functions. Management plans to increase accounting staffing to remediate this.
- Partnership Risks: The company relies on a Joint Development Agreement (JDA) with Bayer. There is no assurance that a royalty-bearing license agreement will be concluded or that terms will be favorable.
Investor Verification Checklist
- Cash Runway: Verify if the $7.3 million cash balance is sufficient to fund the planned clinical trials for ATR-12 and ATR-04 through 2025 without further dilution.
- Warrant Liability: Confirm the accounting treatment and future volatility impact of the Class A Warrants issued in July 2024, which were reclassified from liability to equity following a price reset.
- Internal Control Remediation: Monitor progress on hiring accounting staff to address the material weakness in segregation of duties.
- Bayer JDA Status: Track the status of negotiations for the exclusive royalty-bearing license with Bayer, as this is a key potential revenue stream.
- Dilution Risk: Assess the impact of the 13.3 million warrants outstanding (exercise price $0.70) on future share count and earnings per share.